Jason Gerberry
BofA Securities, Research Division

Company presenter at the BofA Annual Healthcare Conference. My name is Jason Gerberry. I cover pharma and biotech, and I'm pleased to be introducing Amylyx Pharmaceuticals and Joshua Cohen, Co-Chief Executive Officer; This is an interesting time for Amylyx on the cusp of pivotal Phase III data expected in the third quarter, a transformational event. So I imagine a lot of our discussion is going to be focused on the lead program for PBH. So Josh, thanks for joining us.

Joshua Cohen
Co-Founder, Co-CEO & Director

Yes. Thank you so much for having us.

Jason Gerberry
BofA Securities, Research Division

So fresh off of 3Q and I guess, ahead of the pivotal LUCIDITY trial. Maybe if you could just talk a little bit about the trial design, some of the questions that it's designed to answer. And if successful, how this could be an advancement for patients with PBH, this sort of frame and then we'll go from there.

Joshua Cohen
Co-Founder, Co-CEO & Director

Sure. So we're very excited about the Phase III readout expected next quarter. Avexitide, our lead asset has been through 5 prior trials, all of which showed highly statistically significant effects on glucose and insulin. And then in the Phase II and Phase IIb, we studied the rate of Level 2 and Level 3 hypoglycemia, which showed quite a strong effect as well.

So under that backdrop for the Phase III, our goal is to try to keep as much consistent as we possibly could. So very similar inclusion/exclusion criteria, looking at the